As program director for Type 1 Diabetes TrialNet, I oversee a large clinical trial network of international studies that address prevention of and early intervention in type 1 diabetes, as well as the natural history of this disease. I also serve as the executive secretary for the TrialNet Data and Safety Monitoring Board as well as the TrialNet External Evaluation Committee. As program director for the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study, I oversee the administrative aspects of the DCCT/EDIC Coordinating Center and the DCCT/EDIC Administrative Core and serve as the executive secretary for the DCCT/EDIC Observational Study Monitoring Board and the DCCT/EDIC External Evaluation Committee. As the program officer for the Genetic Metabolic Diseases grant portfolio, I oversee all aspects of multiple grants focusing on a variety of inborn errors of metabolism, including grants focusing on gene therapy.
My responsibilities also include membership on the NIH Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt-Jakob Disease. In this capacity, I review all deaths occurring in members of the cohort treated with cadaverine hGH through the National Hormone and Pituitary Program. I serve as a member of the NIDDK Clinical Studies Working Group and of the Division of Diabetes, Endocrinology, and Metabolic Diseases Clinical Working Group. I am also the Chair of the Diabetes Group in the Trans-NIH Biomarkers in Pediatric Therapeutics Special Interest Group. In addition, I am a special volunteer for the Pediatric Endocrinology Clinic where I evaluate and treat pediatric endocrinology patients and I train NICHD’s pediatric endocrinology fellows.